Role of new anticoagulants as adjunctive therapy during thrombolysis

This publication has 27 references indexed in Scilit:

• Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors.
  Journal of Clinical Investigation, 1990
• Heparin versus aspirin after recombinant tissue plasminogen activator therapy in myocardial infarction: A randomized trial
  Journal of the American College of Cardiology, 1990
• Induction of marked thrombin activity by pharmacologic concentrations of plasminogen activators in nonanticoagulated whole blood
  Thrombosis Research, 1989
• Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin versus recombinant hirudin, a specific thrombin inhibitor.
  Circulation, 1989
• Evidence for the presence of tissue factor activity on subendothelium
  Blood, 1989
• Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
  Circulation, 1988
• Paradoxic elevation of fibrinopeptide A after streptokinase: Evidence for continued thrombosis despite intense fibrinolysis
  Journal of the American College of Cardiology, 1987
• Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin.
  Circulation, 1986
• Importance of continued activation of thrombin reflected by fibrinopeptide A to the efficacy of thrombolysis
  Journal of the American College of Cardiology, 1986
• Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion.
  Circulation, 1986